Venenum Biodesign

A Member of Genesis Biotechnology Group

Careers Page

Please view our career page for future employment with Venenum Biodesign.

View Job Postings


VENENUM Biodesign is advancing multiple programs in important therapeutic areas including our most advanced programs targeting Clostridium difficile and Diabetes. In our Clostridium difficile program, we have novel chemotypes advancing that target C. difficile toxin A/B inhibition. Our diabetes program has novel compounds that are targeting the TGR5 receptor in the GI tract and producing a robust GLP-1 effect in animal models. Currently, both programs are advancing in lead optimization.